Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8541738 | 1.00 | ATM (0.43) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9381292 | 1.00 | ATM (0.43) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9041010 | 1.00 | ATM (0.43) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9728021 | 1.00 | ATM (0.43) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL5108204 | 1.00 | ATM (0.43) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9204236 | 0.91 | RAB9A (0.40) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9728199 | 0.91 | RAB9A (0.40) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9202630 | 0.91 | RAB9A (0.40) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9207938 | 0.91 | RAB9A (0.40) | ATMTDP1ALDH1A1MAPTHPGD | |
| SCHEMBL9728231 | 0.89 | MAPT (0.42) | ATMTDP1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342005-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| US-7041836-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050209212-A1 | Antibiotic compounds | ASTRAZENECA UK LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-20030144264-A1 | Antibiotic compounds | ZENECA LIMITED | 2003-07-31 | — | — | US | disclosed |
| US-6521612-B2 | Antibiotic against grampositive, gramnegative bacteria | ZENECA LTD. (GB) | 2003-02-18 | — | — | US | disclosed |
| US-6436921-B1 | HAVE LOW MINIMUM INHIBITORY CONCENTRATIONS FOR GRAMPOSITIVE AND GRAMNEGATIVE STRAINS, ARE STABLE AGAINST DEGRADATION BY RENAL DEHYDROPEPTIDASE-I AND HAVE EXCELLENT BIOAVAILABILITY | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2002-08-20 | — | — | US | disclosed |
| US-20020042408-A1 | Antibiotic compounds | ZENECA LIMITED | 2002-04-11 | — | — | US | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| EP-1019387-A1 | DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0590885-B1 | Antibiotic carbapenem compounds | ZENECA LTD (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993019070-A1 | CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
| EP-0562855-A1 | Carbapenem compounds as antibiotics | ZENECA LIMITED (GB) | 1993-09-29 | — | — | EP | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-5227376-A | Quaternary ammonium carbapenem antibiotics | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| US-5122604-A | 2-(2-Carbonyl-substituted pyrrolidin-4-yl)carbapenems and -penems; microbiocides | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0442497-A1 | Novel beta-lactam compounds and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4943569-A | B-lactam compounds | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1990-07-24 | — | — | US | disclosed |
| US-4933333-A | β-lactam compounds | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0126587-A1 | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209212-A1 | Antibiotic compounds | NRDC, NPR3, NGLY1 | ATM 3490/4885TDP1 4234/4885ALDH1A1 3269/4885 |
| US-20020042408-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | ATM 3895/4885TDP1 2401/4885ALDH1A1 1382/4885 |
| US-20030144264-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | ATM 3950/4885TDP1 2436/4885ALDH1A1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.